Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The current standard-of-care for Hairy Cell Leukemia involves chemotherapy, with agents such
as cladribine or pentostatin. Chemotherapy is associated with infection, low blood counts and
predisposition to future cancers. This study tests a new drug combination for the treatment
of hairy cell leukemia. The treatment involves 8 weeks of treatment with an oral drug called
vemurafenib and 8 doses of an intravenous medication called rituximab. The goal of this study
is to see whether this treatment is better tolerated and more effective than the currently
used treatment in this disease. In addition, this study uses a lower dose of vemurafenib than
previous studies have used, with the goal of minimizing side effects from this medication.